StockNews.AI
SPNT
StockNews.AI
5 hrs

SiriusPoint Announces Sale of ArmadaCare MGA for $250m with Long Term Capacity Deal Until 2030

1. SiriusPoint sells ArmadaCare to Ambac for $250 million. 2. The sale will unlock off-balance sheet value and boost book value by 10%. 3. SiriusPoint anticipates a pre-tax gain of $220-230 million from the sale. 4. Partnership with Armada continues until 2030, aiding operational stability. 5. SiriusPoint's target return on equity remains at 12%-15%.

7m saved
Insight
Article

FAQ

Why Bullish?

The significant pre-tax gain from the sale is likely to enhance investor sentiment, similar to past successful divestitures that improved stock performance.

How important is it?

The article discusses a significant financial transaction that directly affects SPNT's capital and growth potential, making it highly relevant.

Why Short Term?

The immediate financial gain and increased book value may impact SPNT's stock positively in the upcoming quarter.

Related Companies

AMBC
September 29, 2025 16:30 ET  | Source: SiriusPoint Ltd. HAMILTON, Bermuda, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced its agreement to sell wholly owned supplemental health insurance program manager, ArmadaCare (“Armada”) to Ambac Financial Group Inc. (“Ambac”) for $250 million. SiriusPoint will continue its capacity partnership with Armada until the end of 2030. Upon completion of the sale, SiriusPoint will recognize a pre-tax gain of $220-230 million, with the transaction valuing Armada at approximately 14x EBITDA1. Pro-forma tangible book value is expected to increase by approximately 10% upon close. Scott Egan, SiriusPoint’s Chief Executive Officer, said: “The sale of our equity stake is an important step in unlocking the significant off-balance sheet value of Armada. We look forward to continuing our strong partnership with the team through our long-term capacity agreement. “We are proud of our leading capabilities in the Accident & Health segment, which includes our ownership of premier travel platform International Medical Group (IMG), and we see attractive growth opportunities for our A&H business going forward. “We reaffirm our across-the-cycle target return on equity of 12% to 15%.” The transaction is expected to close in the fourth quarter, subject to customary closing conditions and receipt of regulatory approvals. Jefferies LLC served as SiriusPoint’s exclusive financial advisor and Paul Hastings LLP served as legal advisor in the sale of Armada. About SiriusPointSiriusPoint is a global underwriter of insurance and reinsurance providing solutions to clients and brokers around the world. Bermuda-headquartered with offices in New York, London, Stockholm and other locations, we are listed on the New York Stock Exchange (SPNT). We have licenses to write Property & Casualty and Accident & Health insurance and reinsurance globally. Our offering and distribution capabilities are strengthened by a portfolio of strategic partnerships with Managing General Agents and Program Administrators. With approximately $2.8 billion total capital, SiriusPoint’s operating companies have a financial strength rating of A- (Excellent) from AM Best, S&P and Fitch, and A3 from Moody’s. For more information, please visit https://www.siriuspt.com/ About ArmadaCareA leading insurance program manager, ArmadaCare delivers uncommon health insurance solutions designed to enhance ordinary health benefits. With the steadfast belief that health insurance should be better, ArmadaCare’s plans fill voids in coverage for routine and unexpected healthcare expenses, offer valuable health and productivity support services and invite usage with modern conveniences and people-first service. The result gives our clients the edge they need to retain, recruit and reward key talent. Learn more at www.ArmadaCare.com About AmbacAmbac Financial Group, Inc. (“Ambac” or “AFG”) is an insurance holding company headquartered in New York City. Ambac consists of a diverse mix of specialty insurance underwriting and distribution businesses in the U.S. and U.K. Ambac’s common stock trades on the New York Stock Exchange under the symbol “AMBC”. For more information, please go to www.ambac.com Forward-Looking StatementsWe make statements in this press release that are forward-looking statements within the meaning of the U.S. federal securities laws. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the U.S. Federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those contained in the forward-looking statements. These risks and uncertainties include, but are not limited to, the impact of general economic conditions and conditions affecting the insurance and reinsurance industry; the adequacy of our reserves; fluctuation in the results of operations; pandemic or other catastrophic event; uncertainty of success in investing in early-stage companies, such as the risk of loss of an initial investment, highly variable returns on investments, delay in receiving return on investment and difficulty in liquidating the investment; our ability to assess underwriting risk, trends in rates for property and casualty insurance and reinsurance, competition, investment market and investment income fluctuations; trends in insured and paid losses; regulatory and legal uncertainties; and other risk factors described in SiriusPoint’s Annual Report on Form 10-K for the period ended December 31, 2024.  Except as required by applicable law or regulation, we disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, or new information, data or methods, future events or other circumstances after the date of this press release. Contacts Investor RelationsLiam Blackledge, SiriusPointLiam.Blackledge@siriuspt.com+44 203 772 3082 MediaSarah Hills, Rein4cesarah.hills@rein4ce.co.uk+44 7718 882011 1 Based on Last Twelve Months Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA).

Related News